<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary complications of allogeneic hematopoietic cell transplantation: Postengraftment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary complications of allogeneic hematopoietic cell transplantation: Postengraftment</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pulmonary complications of allogeneic hematopoietic cell transplantation: Postengraftment</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Disease process</td> <td class="subtitle1">Risk factors</td> <td class="subtitle1">Associated manifestations</td> <td class="subtitle1">Radiographic findings</td> <td class="subtitle1">Useful diagnostic tests</td> <td class="subtitle1">Lung biopsy needed</td> </tr> <tr class="divider_top"> <td>Bacterial pneumonia</td> <td> </td> <td> </td> <td> <p>Focal or patchy consolidation, may be peribronchial</p> <p>Occasionally mass-like "round-pneumonia"</p> </td> <td>Blood cultures, Legionella and pneumococcal urinary antigens, BAL for Gram stain and aerobic and anaerobic cultures, Legionella culture, Mycoplasma PCR, and modified AFB stain and culture for Nocardia</td> <td>Rarely</td> </tr> <tr class="divider_top"> <td>Mycobacterial pneumonia</td> <td>Total body irradiation, chronic GVHD</td> <td>M. haemophilum is associated with skin nodules and/or joint inflammation</td> <td>Miliary pattern</td> <td>TST after HCT not helpful; AFB staining and cultures of induced sputum and BAL are helpful</td> <td>Rarely</td> </tr> <tr class="divider_top"> <td>CMV pneumonitis</td> <td>Seropositive recipient with seronegative donor; delayed reconstitution, prior treatment for CMV</td> <td> </td> <td>CT: patchy or diffuse ground-glass opacities, patchy consolidation, small nodular opacities; rarely tree-in-bud pattern</td> <td>Serology, blood test for pp65 antigen or CMV PCR, BAL and endobronchial brush for cytologic examination for inclusion bodies and BAL shell vial cultures for CMV</td> <td>Rarely</td> </tr> <tr class="divider_top"> <td>Respiratory viruses</td> <td>Exposure to someone with active viral infection</td> <td>URI symptoms prior to onset of lower respiratory tract symptoms</td> <td>Diffuse ground glass opacities are the most common</td> <td>PCR, culture, or rapid immunofluorescence of nasopharyngeal lavage or swab and BAL fluid</td> <td>Sometimes to completely exclude other possibilities</td> </tr> <tr class="divider_top"> <td>Fungal infection (eg, invasive aspergillosis, Fusarium, agents of mucormycosis, Candida, Scedosporium, Pneumocystis)</td> <td>Presence and severity GVHD, older patient age, cytopenia, CMV infection</td> <td> </td> <td>Focal nodular and consolidative opacities, "halo sign," "reverse halo sign," sometimes subpleural wedge-shaped densities</td> <td>Broad microbiologic testing of blood and BAL; blood tests for β-D-glucan and Aspergillus galactomannan EIA; BAL for Aspergillus galactomannan EIA; and induced sputum and BAL for Pneumocystis staining</td> <td>Sometimes when cultures are negative and no response to initial therapy</td> </tr> <tr class="divider_top"> <td>Idiopathic pneumonia syndrome</td> <td>Busulfan, high dose cyclophosphamide, radiation, nonmyeloablative conditioning regimen</td> <td> </td> <td>Extensive opacities</td> <td>Negative stains, cultures, antigen testing, and PCR of blood, sputum, urine, and BAL</td> <td>Yes, either transbronchial or surgical</td> </tr> <tr class="divider_top"> <td>Heart failure</td> <td>Anthracycline treatment; coronary artery disease</td> <td>Bibasilar crackles, peripheral edema</td> <td>CT: patchy or diffuse ground-glass opacities, pleural effusion</td> <td>BNP, echocardiogram</td> <td>No</td> </tr> <tr class="divider_top"> <td>Diffuse alveolar hemorrhage</td> <td>Underlying mucopolysaccharidosis</td> <td> </td> <td>CT: patchy or diffuse opacities, may have air bronchograms</td> <td>BAL showing increasingly bloody return in sequential lavages and &gt;20 percent hemosiderin-laden macrophages</td> <td>Not usually</td> </tr> <tr class="divider_top"> <td>Connective tissue disease</td> <td>Myeloablative conditioning regimen</td> <td>Extrapulmonary manifestations such as dry mouth/dry eyes, joint pain/swelling, muscle weakness</td> <td>CT: subpleural, ground-glass opacities; septal thickening</td> <td>Autoantibody tests positive</td> <td>Often to identify specific type of interstitial pneumonitis</td> </tr> <tr class="divider_top"> <td>Cryptogenic organizing pneumonia/organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia)</td> <td>Irradiation, CMV infection, HCT associated connective tissue disease, chronic GVHD</td> <td> </td> <td>CT: patchy air-space consolidation, ground-glass opacities, small nodular opacities, "reverse halo sign"</td> <td>Lung biopsy</td> <td>Yes</td> </tr> <tr class="divider_top"> <td>Bronchiolitis obliterans </td> <td>Chronic GVHD, postviral</td> <td> </td> <td>CT initially clear; as progresses, CT may show mosaic ground glass opacities and bronchiectasis</td> <td> <p>Spirometry showing airflow limitation</p> <p>Skin biopsy for GVHD</p> </td> <td>Sometimes, if diagnosis uncertain </td> </tr> <tr class="divider_top"> <td>Malignancy</td> <td>Underlying lymphoma, EBV infection in posttransplant lymphoproliferative disorder</td> <td> </td> <td>Nodular opacities, lymphangitic pattern</td> <td>BAL cytology and flow cytometry, biopsy</td> <td>Biopsy usually needed</td> </tr> <tr class="divider_top"> <td>Pulmonary alveolar proteinosis</td> <td>HCT for myeloid disorder</td> <td> </td> <td>Perihilar opacities in a "bat-wing" distribution often with air bronchograms</td> <td>Bronchoalveolar lavage showing characteristic milky appearance and positive stain for lipoproteins </td> <td>Not usually</td> </tr> <tr class="divider_top"> <td>Pulmonary cytolytic thrombi</td> <td>Chronic GVHD is a risk factor</td> <td>Low grade fever, cough</td> <td>CT: peripheral nodules</td> <td>BAL to rule out infection; lung biopsy</td> <td>Yes, findings are basophilic cytolytic thrombi in the small to medium distal pulmonary vessels with entrapped monocytes</td> </tr> <tr class="divider_top"> <td>Pulmonary veno-occlusive disease</td> <td>Onset after first 100 days, chronic GVHD</td> <td>Reduced DLCO</td> <td>CXR: pleural effusion and Kerley B lines; CT chest: centrilobular ground glass opacities; no emboli on CTPA</td> <td>Right heart catheterization; BAL showing occult hemorrhage</td> <td>For definitive diagnosis</td> </tr> <tr class="divider_top"> <td>Drug toxicity</td> <td>History of pneumotoxic drug use (eg, busulfan, cyclophosphamide)</td> <td>May be associated with rash, peripheral eosinophilia</td> <td>Varied</td> <td>Increased BAL eosinophils may be seen; other processes excluded by negative blood and BAL stains and cultures, negative fungal studies</td> <td>Sometimes to completely exclude other possibilities</td> </tr> <tr class="divider_top"> <td>Radiation pneumonitis</td> <td>History of radiation therapy involving lungs</td> <td> <p>Acute: onset usually 4 to 12 weeks following irradiation</p> <p>Late: onset after 6 to 12 months</p> </td> <td> <p>Acute CT: ground-glass attenuation within the area of irradiated lung</p> <p>Late CT: linear opacities (scarring) or an area of dense consolidation and volume loss</p> </td> <td>Other processes excluded by negative blood and BAL stains and cultures, negative fungal studies</td> <td>Sometimes to completely exclude other possibilities</td> </tr> </tbody></table></div><div class="graphic_lgnd">Selection of specific diagnostic tests is based on clinical features and results of prior testing.</div><div class="graphic_footnotes">BAL: bronchoalveolar lavage; PCR: polymerase chain reaction; AFB: acid-fast bacillus; GVHD: graft-versus-host disease; TST: tuberculin skin test; HCT: hematopoietic cell transplantation; CMV: cytomegalovirus; CT: computed tomography; URI: upper respiratory infection; EIA: enzyme immunoassay; BNP: Brain natriuretic peptide; EBV: Epstein-Barr virus; DLCO: diffusing capacity for carbon monoxide; CXR: chest radiograph; CTPA: computed tomography pulmonary angiography.</div><div id="graphicVersion">Graphic 83195 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
